| First Author | Zhou Z | Year | 2024 |
| Journal | Immunity | Volume | 57 |
| Issue | 3 | Pages | 513-527.e6 |
| PubMed ID | 38262419 | Mgi Jnum | J:346148 |
| Mgi Id | MGI:7614064 | Doi | 10.1016/j.immuni.2024.01.001 |
| Citation | Zhou Z, et al. (2024) Type 2 cytokine signaling in macrophages protects from cellular senescence and organismal aging. Immunity 57(3):513-527.e6 |
| abstractText | Accumulation of senescent cells in organs and tissues is a hallmark of aging and known to contribute to age-related diseases. Although aging-associated immune dysfunction, or immunosenescence, is known to contribute to this process, the underlying mechanism remains elusive. Here, we report that type 2 cytokine signaling deficiency accelerated aging and, conversely, that the interleukin-4 (IL-4)-STAT6 pathway protected macrophages from senescence. Mechanistically, activated STAT6 promoted the expression of genes involved in DNA repair both via homologous recombination and Fanconi anemia pathways. Conversely, STAT6 deficiency induced release of nuclear DNA into the cytoplasm to promote tissue inflammation and organismal aging. Importantly, we demonstrate that IL-4 treatment prevented macrophage senescence and improved the health span of aged mice to an extent comparable to senolytic treatment, with further additive effects when combined. Together, our findings support that type 2 cytokine signaling protects macrophages from immunosenescence and thus hold therapeutic potential for improving healthy aging. |
